Izotropic Corp. Advances Breast Cancer Imaging with Exclusive Breast CT Technology

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is making strides in breast cancer imaging with its exclusive global rights to the Breast CT technology developed at UC Davis. This innovation positions the company as a leader in addressing the limitations of conventional breast imaging, particularly for dense breast tissue. The IzoView technology offers a proprietary, patient-centric alternative to mammography, aiming to enhance diagnostic confidence and improve the patient experience.

The company has achieved regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial, marking a significant milestone in its mission to revolutionize breast cancer screening and diagnosis. With a comprehensive business and financial plan, Izotropic is set to execute across clinical, regulatory, and commercial milestones, targeting a clear unmet need in a multibillion-dollar global market.

Izotropic's efforts are supported by awareness campaigns, including a dedicated website and a company podcast, designed to drive engagement and increase investor visibility. As a medical device company focused exclusively on breast cancer imaging, Izotropic is committed to delivering transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows.

For more information on Izotropic Corp. and its advancements in breast cancer imaging, visit https://ibn.fm/IZOZF.